Search

AstraZeneca PLC

Avatud

SektorTervishoid

10,346 -0.25

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

10308

Max

10502

Põhinäitajad

By Trading Economics

Sissetulek

237M

1.7B

Müük

1.3B

15B

P/E

Sektori keskmine

29.777

57.333

Aktsiakasum

2.09

Dividenditootlus

2.43

Kasumimarginaal

11.188

Töötajad

94,300

EBITDA

-235M

4.4B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+29.27% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.43%

2.63%

Järgmine tulemuste avaldamine

29. apr 2025

Turustatistika

By TradingEconomics

Turukapital

-19B

157B

Eelmine avamishind

10346.25

Eelmine sulgemishind

10346

AstraZeneca PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. märts 2025, 03:15 UTC

Suurimad hinnamuutused turgudel

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

17. märts 2025, 07:42 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

15. apr 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9. apr 2025, 07:23 UTC

Market Talk

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3. apr 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3. apr 2025, 08:36 UTC

Market Talk

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3. apr 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31. märts 2025, 09:31 UTC

Kuumad aktsiad

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

17. märts 2025, 14:43 UTC

Market Talk

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

17. märts 2025, 13:55 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

17. märts 2025, 07:04 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca: Transaction Doesn't Affect Fincl Guidance for 2025.

17. märts 2025, 07:03 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca: Acquisition Expected to Close in 2Q 2025

17. märts 2025, 07:03 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca to Pay Up to $575M Upon Development, Regulatory Milestones Being Met

17. märts 2025, 07:01 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca to Make Initial Payment of $425M on Deal Closing

17. märts 2025, 07:01 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca Buying EsoBiotec for up to $1B

17. märts 2025, 07:01 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca to Buy EsoBiotec to Advance Cell Therapy Ambition

17. märts 2025, 07:00 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca to Buy EsoBiotec

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26. veebr 2025, 14:59 UTC

Market Talk

AstraZeneca's Breast-Cancer Drug Results Seen as Positive Surprise -- Market Talk

26. veebr 2025, 08:04 UTC

Market Talk
Tulu

AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

20. veebr 2025, 11:34 UTC

Omandamised, ülevõtmised, äriostud

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20. veebr 2025, 11:34 UTC

Omandamised, ülevõtmised, äriostud

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20. veebr 2025, 11:33 UTC

Omandamised, ülevõtmised, äriostud

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20. veebr 2025, 11:33 UTC

Omandamised, ülevõtmised, äriostud

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20. veebr 2025, 11:31 UTC

Omandamised, ülevõtmised, äriostud

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20. veebr 2025, 11:30 UTC

Omandamised, ülevõtmised, äriostud

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

13. veebr 2025, 10:49 UTC

Market Talk
Tulu

AstraZeneca Stands Out With Catalyst-Rich, Diversified Pipeline -- Market Talk

7. veebr 2025, 10:30 UTC

Peamised uudised

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6. veebr 2025, 15:18 UTC

Market Talk

U.K. Health System Needs to Improve Investment Environment, AstraZeneca CEO Says -- Market Talk

6. veebr 2025, 13:24 UTC

Market Talk

AstraZeneca's Increased R&D Spend Is a Positive -- Market Talk

AstraZeneca PLC Prognoos

Hinnasiht

By TipRanks

29.27% tõus

12 kuu keskmine prognoos

Keskmine 13,501.38 GBX  29.27%

Kõrge 17,200 GBX

Madal 10,900 GBX

Põhineb 15 Wall Streeti analüütiku instrumendi AstraZeneca PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

15 ratings

11

Osta

4

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.